(The following press release from Merck KGaA was received by e-mail. It was not confirmed by the sender.) News Release Your Contact Phyllis Carter Phone .+49 6151 72-3321 Merck: Phase III Trial of Cilengitide Did Not Meet Primary Endpoint in Patients With Newly Diagnosed Glioblastoma • Patients with newly diagnosed glioblastoma and methylated MGMT gene promoter status did not live significantly longer when treated with cilengitide plus chemoradiotherapy Darmstadt, Germany, February 25, 2013 – Merck announced today that the Phase III CENTRIC(a) trial of the investigational integrin inhibitor cilengitide did not meet its primary endpoint of significantly increasing overall survival when added to the current standard chemoradiotherapy regimen (temozolomide and radiotherapy). CENTRIC includes patients with newly diagnosed glioblastoma and methylated O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter status. The trial was planned and is being conducted in partnership with the European Organisation for Research and Treatment of Cancer (EORTC). Detailed trial results will be submitted for presentation at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting and publication in a peer-reviewed journal. The complete news release can be downloaded at the following link: http://news.merck.de/N/0/BE2FE07AD630830EC1257B1D001F007B/$File/CENTRIC-E.pdf News releases from Merck KGaA, Darmstadt, Germany, are available at this address: www.merckgroup.com/media or for residents in the USA and Canada at www.emdgroup.com/media In case you are a resident of the USA or Canada please go to http://www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may change your subscription at any time by following either one of the following links: www.merckgroup.com/subscribe or www.emdgroup.com/subscribe And please feel free to unsubscribe this service with either www.merckgroup.com/subscribe or www.emdgroup.com/unsubscribe Thank you very much! Merck KGaA ,Darmstadt, Germany External Communications E-mail: Media.Relations@merck.de Hotline: +49 (0) 6151/72-5000 This message and any attachment are confidential and may be privileged or otherwise protected from disclosure. If you are not the intended recipient, you must not copy this message or attachment or disclose the contents to any other person. If you have received this transmission in error, please notify the sender immediately and delete the message and any attachment from your system. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not accept liability for any omissions or errors in this message which may arise as a result of E-Mail-transmission or for damages resulting from any unauthorized changes of the content of this message and any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not guarantee that this message is free of viruses and does not accept liability for any damages caused by any virus transmitted therewith. Click http://disclaimer.merck.de to access the German, French, Spanish and Portuguese versions of this disclaimer.
MERCK KGAA SAYS CILENGITIDE PHASE III TRIAL MISSES ENDPOINT(ENG)
Press spacebar to pause and continue. Press esc to stop.